Angion Biomedica analyst ratings
Angion Biomedica analyst ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 07/18/2022 | — | HC Wainwright & Co. | Downgrades | Buy → Neutral | |
| 06/30/2022 | — | Oppenheimer | Downgrades | Outperform → Perform | |
| 06/30/2022 | 41.51% | Stifel | $5 → $1.5 | Downgrades | Buy → Hold |
| 05/23/2022 | 2541.51% | HC Wainwright & Co. | $32 → $28 | Maintains | Buy |
| 04/18/2022 | 2918.87% | HC Wainwright & Co. | $50 → $32 | Maintains | Buy |
| 12/10/2021 | 654.72% | Oppenheimer | $15 → $8 | Maintains | Outperform |
| 11/09/2021 | 4616.98% | HC Wainwright & Co. | $100 → $50 | Maintains | Buy |
| 10/27/2021 | 1315.09% | Stifel | $40 → $15 | Maintains | Buy |
| 03/02/2021 | — | Cowen & Co. | Initiates Coverage On | → Outperform | |
| 03/02/2021 | 3484.91% | Oppenheimer | → $38 | Initiates Coverage On | → Outperform |
| 03/02/2021 | 3673.58% | Stifel | → $40 | Initiates Coverage On | → Buy |
| 03/01/2021 | 9333.96% | HC Wainwright & Co. | → $100 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目标价格变动 | 评级变动 | 之前/当前的评级 |
|---|---|---|---|---|---|
| 07/18/2022 | — | HC Wainwright & Co. | 降级 | 买入 → 中性 | |
| 06/30/2022 | — | 奥本海默 | 降级 | 跑赢大盘 → 表现 | |
| 06/30/2022 | 41.51% | Stifel | 5 美元 → 1.5 美元 | 降级 | 买入 → 持有 |
| 05/23/2022 | 2541.51% | HC Wainwright & Co. | 32 美元 → 28 美元 | 维护 | 买 |
| 04/18/2022 | 2918.87% | HC Wainwright & Co. | 50 美元 → 32 美元 | 维护 | 买 |
| 12/10/2021 | 654.72% | 奥本海默 | 15 美元 → 8 美元 | 维护 | 跑赢大盘 |
| 2021 年 9 月 11 日 | 4616.98% | HC Wainwright & Co. | 100 美元 → 50 美元 | 维护 | 买 |
| 10/27/2021 | 1315.09% | Stifel | 40 美元 → 15 美元 | 维护 | 买 |
| 2021 年 2 月 3 日 | — | Cowen & Co. | 启动覆盖范围开启 | → 跑赢大盘 | |
| 2021 年 2 月 3 日 | 3484.91% | 奥本海默 | → 38 美元 | 启动覆盖范围开启 | → 跑赢大盘 |
| 2021 年 2 月 3 日 | 3673.58% | Stifel | → 40 美元 | 启动覆盖范围开启 | → 购买 |
| 2021 年 1 月 3 日 | 9333.96% | HC Wainwright & Co. | → 100 美元 | 启动覆盖范围开启 | → 购买 |
Angion Biomedica Questions & Answers
心绞痛生物医学问答
The latest price target for Angion Biomedica (NASDAQ: ANGN) was reported by HC Wainwright & Co. on July 18, 2022. The analyst firm set a price target for $0.00 expecting ANGN to fall to within 12 months (a possible -100.00% downside). 8 analyst firms have reported ratings in the last year.
HC Wainwright & Co. 于2022年7月18日公布了安吉恩生物医药（纳斯达克股票代码：ANGN）的最新目标股价。该分析公司将目标股价定为0.00美元，预计ANGN将在12个月内跌至12个月内（可能下跌-100.00％）。去年有8家分析公司公布了评级。
The latest analyst rating for Angion Biomedica (NASDAQ: ANGN) was provided by HC Wainwright & Co., and Angion Biomedica downgraded their neutral rating.
安吉恩生物医学（纳斯达克股票代码：ANGN）的最新分析师评级由HC Wainwright & Co. 提供，Angion Biomedica下调了中性评级。
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Angion Biomedica, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Angion Biomedica was filed on July 18, 2022 so you should expect the next rating to be made available sometime around July 18, 2023.
分析师在进行了广泛的研究后得出了股票评级，其中包括浏览公开财务报表，与Angion Biomedica的高管和客户交谈，以及听取财报电话会议。大多数分析师每三个月做一次这样的评级，因此每家公司每年应该获得4次评级。Angion Biomedica的最新评级是在2022年7月18日发布的，因此您应该预计下一个评级将在2023年7月18日左右公布。
While ratings are subjective and will change, the latest Angion Biomedica (ANGN) rating was a downgraded with a price target of $0.00 to $0.00. The current price Angion Biomedica (ANGN) is trading at is $1.06, which is out of the analyst's predicted range.
尽管评级是主观的，并且会发生变化，但最新的安吉恩生物医学（ANGN）评级已下调，目标股价为0.00美元至0.00美元。Angion Biomedica（ANGN）目前的交易价格为1.06美元，超出了分析师的预期区间。